Clinical trial · Observational
Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is a malignant tumor with the highest morbidity and mortality among women worldwide. Accurate staging of axillary lymph nodes is critical for metastatic assessment and decisions regarding treatment modalities in breast cancer patient. Among patients who underwent sentinel lymph node biopsy, about 70 % of the patients had negative pathological results and in other words, these 70 % of the patients received unnecessary surgery. At present, imaging and pathological diagnosis is the main measure of lymph node metastasis in breast cancer. However, limitations remained. Artificial intelligence, including deep learning and machine learning algorithms, has emerged as a possible technique, which can make a more accuracy prediction through machine-based collection, learning and processing of previous information, especially in radiology and pathology-based diagnosis. With the intensification of the concept of precision medicine and the development of non-invasive technology, the investigators intend to use the artificial intelligence technology to develop a serum and tissue-based predictive model for sentinel lymph node metastasis diagnosis combined with imaging and pathological information, providing specific, efficient and non-invasive biological indicators for the monitoring and early intervention of lymph node metastasis in patient with breast cancer. Therefore, the investigators retrospectively include serum samples from early breast cancer patients undergoing sentinel lymph node biopsy, including a discovery cohort and a modeling cohort. Metabolites were detected and screened in the discovery cohort and then as the target metabolites for targeted detection in the modeling cohort. Combined with preoperative imaging and pathological information, a prediction model of breast cancer sentinel lymph node metastasis based on serum metabolites would be established. Subsequently, multi-center breast cancer patients will prospectively be included to verify the accuracy and stability of the model.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lymph Node Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Discovering cohort
- description
- Discovering cohort was used for the discovery and screening of metabolic differences. Two groups were included-SLN+ group and SLN- group, meaning the breast cancer patients with/without sentinel lymph node metastasis respectively. Abundance and distribution of serum and tissue metabolites in this cohort of patients would be observed.
- label
- Modeling cohort
- description
- Modeling cohort refer to the cohort of patients included for targeted metabolites detection. Two groups were included-SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and a predictive model would be established using the data of this cohort.
- label
- Validation cohort
- description
- Validation cohort means a cohort of patients included to validate the prediction model established in the modeling stage. Patients of validation cohort will be enrolled from several different hospitals. Also, it included SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and the accuracy and stability of prediction model will be verified in this cohort.
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of breast cancer * No preoperative therapy including chemotherapy or endocrine therapy * No distant metastasis * Underwent mastectomy or breast-conserving surgery with sentinel lymph node biopsy * Agreed to provide preoperative peripheral blood samples * Had access to imaging, pathological and follow-up data for preoperative and postoperative evaluation of the disease Exclusion Criteria: * Neoadjuvant therapy * Presence of distant metastasis at time of diagnosis * Primary malignancies other than breast cancer * Bilateral breast cancer or previous contralateral breast cancer * Undergo modified radical surgery for breast cancer without sentinel lymph node biopsy * Incomplete pathological data and follow-up data * Pregnancy and other conditions determined by the investigator to be ineligible for inclusion in the study
References
Publications (8)
- BACKGROUNDSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- BACKGROUNDXu Y, Su GH, Ma D, Xiao Y, Shao ZM, Jiang YZ. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduct Target Ther. 2021 Aug 20;6(1):312. doi: 10.1038/s41392-021-00729-7. PMID 34417437
- BACKGROUNDZhou H, Zhu L, Song J, Wang G, Li P, Li W, Luo P, Sun X, Wu J, Liu Y, Zhu S, Zhang Y. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022 Mar 25;21(1):86. doi: 10.1186/s12943-022-01556-2. PMID 35337361
- BACKGROUNDRichard V, Davey MG, Annuk H, Miller N, Kerin MJ. The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer. Mol Cancer. 2022 Apr 4;21(1):95. doi: 10.1186/s12943-022-01506-y. PMID 35379239
- BACKGROUNDChayakulkheeree J, Pungrassami D, Prueksadee J. Performance of breast magnetic resonance imaging in axillary nodal staging in newly diagnosed breast cancer patients. Pol J Radiol. 2019 Oct 18;84:e413-e418. doi: 10.5114/pjr.2019.89690. eCollection 2019. PMID 31969959
- BACKGROUNDAlimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet. 2019 Jun;95(6):643-660. doi: 10.1111/cge.13514. Epub 2019 Feb 27. PMID 30671931
- BACKGROUNDIsaksen JL, Baumert M, Hermans ANL, Maleckar M, Linz D. Artificial intelligence for the detection, prediction, and management of atrial fibrillation. Herzschrittmacherther Elektrophysiol. 2022 Mar;33(1):34-41. doi: 10.1007/s00399-022-00839-x. Epub 2022 Feb 11.